🇺🇸 FDA
Pipeline program

Osimertinib

19655

Phase 1 small_molecule active

Quick answer

Osimertinib for Lung Cancer Metastatic is a Phase 1 program (small_molecule) at PUMA BIOTECHNOLOGY, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
PUMA BIOTECHNOLOGY, INC.
Indication
Lung Cancer Metastatic
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials